Niall M B Martin

Niall M. Martin is the Chief Executive Officer of Artios Pharma, Cambridge, UK. Before this, he was Co-founder and Chief Operating Officer at Mission Therapeutics, Cambridge, UK. He has more than 25 years of experience in drug discovery, with a particular focus on DNA repair in oncology, including heading the poly(ADP-ribose) polymerase (PARP) inhibitor programme at KuDOS Pharmaceuticals, Cambridge, UK, that identified the pioneering new drug olaparib.